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Background: Preoperative treatment of resectable liver metastases from colorectal cancer (CRC) is a matter of debate. The aim of
this study was to assess the feasibility and activity of bevacizumab plus FOLFIRI in this setting.
Methods: Patients aged 18–75 years, PS 0–1, with resectable liver-confined metastases from CRC were eligible. They received
bevacizumab 5mg kg 1 followed by irinotecan 180mgm 2, leucovorin 200mgm 2, 5-fluorouracil 400mgm 2 bolus and
5-fluorouracil 2400mgm 2 46-h infusion, biweekly, for 7 cycles. Bevacizumab was stopped at cycle 6. A single-stage, single-arm
phase 2 study design was applied with 1-year progression-free rate as the primary end point, and 39 patients required.
Results: From October 2007 to December 2009, 39 patients were enrolled in a single institution. Objective response rate was
66.7% (95% exact CI: 49.8–80.9). Of these, 37 patients (94.9%) underwent surgery, with a R0 rate of 84.6%. Five patients had a
pathological complete remission (14%). Out of 37 patients, 16 (43.2%) had at least one surgical complication (most frequently
biloma). At 1 year of follow-up, 24 patients were alive and free from disease progression (61.6%, 95% CI: 44.6–76.6). Median PFS
and OS were 14 (95% CI: 11–24) and 38 (95% CI: 28–NA) months, respectively.
Conclusion: Preoperative treatment of patients with resectable liver metastases from CRC with bevacizumab plus FOLFIRI is
feasible, but further studies are needed to define its clinical relevance.
Twenty percent of patients with colorectal cancer (CRC) have
clinical evidence of liver metastases at diagnosis and B50% of
patients will develop liver metastatic disease later (Jemal et al,
2004). Surgery is actually an accepted standard approach to liver-
confined metastases from CRC. However, unfortunately, 70–80%
of patients will relapse in 2 years (Van Cutsem et al, 2006). In the
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past 15 years, new drugs, both cytotoxic and biologic agents, have
been developed that have resulted in significant improvements in
objective response rates and ultimately in overall survival of
patients with metastatic CRC. Neoadjuvant chemotherapy has
been increasingly used in the management of liver-confined
metastases from CRC in the past years, even in patients with
initially resectable disease to increase the complete resection rate
and treat the micrometastatic disease. In addition, neoadjuvant
chemotherapy can be used as a test of in vivo chemosensitivity, and
patients with extremely aggressive disease, who will progress
during preoperative chemotherapy, can be spared useless surgery
(Adam et al, 2004). Postoperative morbidity and mortality remain
the major issues of this approach (Vauthey et al, 2006; Van Cutsem
et al, 2009). In the EORTC 40983 phase 3 trial, a combined
approach of pre- and post-operative chemotherapy with FOLFOX
(six cycles before surgery and six cycles after) slightly improved
progression-free survival with a higher rate of postoperative
complications, all reversible, and no difference in preoperative
mortality (Nordlinger et al, 2008).
The integration of biologic agents into neoadjuvant treatment of
liver metastases from CRC has been mostly investigated for the
treatment of unresectable metastatic disease (Ellis et al, 2005; Saltz
et al, 2008; Van Cutsem et al, 2009; Folprecht et al, 2010; Bertolini
et al, 2011). The feasibility, including perioperative complication
rate and potential impact on postoperative liver regeneration, of
the combination of bevacizumab with oxaliplatin and capecitabine
as preoperative treatment of liver metastases from CRC was
evaluated in a single-arm phase 2 study (Gruenberger et al, 2008).
Bevacizumab was administered up to 5 weeks before surgery. Out
of 56 enrolled patients, 52 underwent potentially curative surgery.
No patients experienced increased bleeding events or wound-
healing complications. Postoperative mortality was null. Normal
liver function and regeneration were observed in 98% of the
patients who underwent resection. The authors concluded that
bevacizumab combined with chemotherapy is a feasible, safe and
active neoadjuvant treatment for liver metastases from CRC. The
combination of bevacizumab with an irinotecan-based chemother-
apy is a standard option in the first-line treatment of metastatic
CRC patients (Hurwitz et al, 2004). To the best of our knowledge,
there are no published data on the use of this combination in the
neoadjuvant setting. We report the results of a single-centre, phase
II study designed to assess the feasibility and activity of
bevacizumab plus FOLFIRI as neoadjuvant treatment of resectable
liver-confined metastases from CRC.
PATIENTS AND METHODS
Eligibility and patient evaluation. Patients aged 18 to 75 years,
with an Eastern Cooperative Group (ECOG) performance status of
0 or 1, were eligible if they had colorectal adenocarcinoma
histologically or cytologically confirmed with resectable liver
metastases. Liver disease was defined resectable when the future
liver remnant volume would be at least 30% of total liver volume
and when two contiguous segments with their own vascularisation
and biliary drainage would be preserved. Patients had to have
normal organ function and urine dipstick of proteinuria o2þ
(patients with proteinuria on baseline dipstick urinalysis X2þ
had to undergo a 24-h urine collection and must have hadp1 g of
protein per 24 h). Previous adjuvant chemotherapy was allowed if
completed 46 months before the enrolment, whereas prior
treatment with bevacizumab or irinotecan was not permitted.
Patients with distant metastases in organs other than the liver were
excluded as well as those who had diagnosis of liver metastases
concomitant to the presence of primary CRC producing a stenosis
of lumen or a full-thickness bowel wall invasion. Prior history of
malignancy other than colorectal, bleeding diathesis, coagulation
disorders, clinically significant cardiovascular disease, recent
coronary artery disease, serious arrhythmias, regular use of
nonsteroidal anti-inflammatory drugs or aspirin (4325mg day 1)
and the presence of ascites were other exclusion criteria. Patients
provided written informed consent. The study was approved by the
Ethical Committee of the National Cancer Institute of Naples,
Naples, Italy.
Treatment. Eligible patients were assigned to receive neoadjuvant
FOLFIRI plus bevacizumab. FOLFIRI was administered intra-
venously (i.v.) every 14 days with irinotecan 180mgm 2 i.v.
infusion on day 1, leucovorin 200mgm 2 i.v. infusion on day 1,
5-fluorouracil 400mgm 2 by i.v. bolus on day 1, 5-fluorouracil
2400mgm 2 46-h continuous infusion; bevacizumab was admi-
nistered at 5mg kg 1 by i.v. infusion over 90min at the first cycle,
and then, if tolerated, over 60min. The treatment was administered
every 14 days, for 7 cycles; bevacizumab was stopped at cycle 6 to
prolong the bevacizumab-free interval and to reduce the risk of
surgical bleeding.
After restaging, patients whose liver metastases were still
confirmed as potentially resectable underwent surgery.
Following surgery, four further cycles of FOLFIRI plus
bevacizumab were planned, with the same dose and schedule
planned.
Assessment of outcomes. Baseline assessment included medical
history, physical examination, haematology, biochemistry, protei-
nuria and blood pressure measurement; all these were repeated
before each cycle of treatment. All patients were evaluated by a
multidisciplinary team composed of an oncologist, a surgeon and a
radiologist at diagnosis and after neoadjuvant chemotherapy before
performing surgery. A surgical evaluation to define liver metastases
as potentially resectable was expected at baseline. Electrocardio-
gram was performed at baseline and then every two cycles.
Tumour response was assessed with computed tomographic
scan after neoadjuvant treatment using RECIST criteria version
1.0. As an exploratory substudy, two FDG PET/CT scans were
included within the flow of examinations planned by the protocol;
results of the substudy will be reported elsewhere.
Liver resection was defined as radical (R0) according to both
macroscopic description of surgery and histological evaluation.
Radical surgery was defined as a margin of at least 1mm.
Pathologic response was classified according to the Mandard
system (Mandard et al, 1994).
Toxicity was assessed according to the Common Toxicity
Criteria Adverse Events 3.0.
Study design. A single-stage, single-arm, phase 2 study design was
applied. With 39 patients enrolled, the study would be powered to
describe an expected proportion of 70±12% rate of patients alive
and disease free at 1 year. Secondary end points were the incidence
of postoperative complications and the antitumour activity in
terms of overall response rate to preoperative chemotherapy. All
descriptive analyses were done on the basis of intention to treat.
RESULTS
From October 2007 to December 2009, 39 patients with liver
metastases from colon (87.2%) or rectal (12.8%) cancer were
enrolled in a single institution. Of these, 27 (69.2%) patients were
diagnosed with a metastatic disease. Out of the 12 patients with a
previous diagnosis, 5 (12.8%) patients had adjuvant chemotherapy
(FOLFOX-4 for 12 cycles) after resection of the primary tumour.
Median age was 58 (range 30–75); males were prevalent (61.5%).
The most frequent comorbidity at enrolment was hypertension,
reported in 38.5% of patients. For two patients, liver metastases
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were erroneously defined as operable at registration; these patients
received planned medical treatment and have been considered in the
following analyses. One further patient, who had been previously
operated for primary colon cancer, was found ineligible a posteriori,
because pathologic examination of the resected liver lesion revealed
a primary liver cancer, not a metastasis from CRC. This patient too
was considered in the analyses. Baseline characteristics of patients
and of the disease are summarised in Table 1.
A total of 37 (94.9%) patients received 6 injections of bevacizumab
associated with the first 6 cycles of chemotherapy; 1 stopped
bevacizumab after 4 administrations (because of thrombosis) and 1
received bevacizumab also combined to the seventh administration of
chemotherapy because it was clear that surgical resection of liver
metastases could not be attempted. Bevacizumab median dose
intensity was 1.7 (range 1.5–2.3) mg kg 1 per week, with a relative
dose intensity of 69% (range 60–29). All the patients received seven
administrations of chemotherapy, as planned. Irinotecan median
dose intensity was 70 (range 41–88) mgm 2 per week, with a
relative dose intensity of 78% (range 45–98). Overall time required to
conclude the planned treatment was quite longer than the 14 planned
weeks; median actual time was 18 weeks (range 14–20). Reasons for
dose delaying were grade 3 neutropenia for 6 patients (15%), CVC-
related complication for 4 patients (10%) and diarrhoea for 2 patients
(5%). In 11% of cases, the delay was due to logistic reasons. As a
consequence, although dose reductions of bevacizumab were never
done and only one patient had a 50% reduction of dose of
chemotherapy because of severe haematologic toxicity, median dose
intensity of bevacizumab and of irinotecan (considered as indicative
for all the cytotoxic drugs) was reduced as compared with the
planned one: 69% (range 60–92) and 78% (range 45–98), respectively.
During neoadjuvant treatment, neutropenia was the most
frequent adverse event (23.1% of patients), grade 3 in 6 cases
(15.4%). Granulocyte colony-stimulating factor (G-CSF) was used
in 8 patients: 6 had grade 3 neutropenia and received G-CSF to
maintain dose intensity, 1 had febrile neutropenia and 1 had
persistent grade 2 neutropenia; erythropoietin was used in 1
patient with grade 2 anaemia. Three patients (two of which already
suffering hypertension at baseline) had grade 3 hypertension.
Diarrhoea was also frequent (23.1% of patients) but severe in only
2 cases (Table 2).
All patients underwent radiologic restaging after neoadjuvant
treatment, before planned surgery. At CT scan evaluation,
according to RECIST, 1 patient (2.6%) had a complete response
and 25 a partial response (64.1%) for an overall objective response
rate of 66.7% (95% exact CI: 49.8–80.9). Two patients (5.1%)
progressed but were still considered operable. Both the two patients
identified as nonoperable shortly after treatment start had stable
disease and did not undergo liver surgery.
In all, 37 patients (94.9%) were operated to resect liver
metastases, with a median interval of 9 weeks from the last
administration of bevacizumab and 6 weeks from the last
administration of chemotherapy. More than half of the operations
were resection of one or two hepatic segments; radiofrequency
ablation of lesions with a maximum diameter of 2 cm was
associated in 8 patients and was always considered radical,
meaning nonresidual tumour left, as it was performed by needle
for treating 4 cm of liver tissue.
Radical surgery (R0) was achieved in 33 (84.6%) of the enrolled
patients. Five patients (12.8%) had a pathological complete
remission and were classified as Tumour Regression Grade
(TRG) 1 according to Mandard system. Twelve patients (30.8%)
had a pathological partial remission (including TRG 2 and 3
according to Mandard system). Out of the four patients not
radically resected, three underwent major surgery but had surgical
margins positive for malignant cells, whereas one patient had only
explorative laparotomy because of the presence of peritoneal
carcinomatosis that was not evident at CT scan.
Out of 37 patients who underwent surgery, 16 (43.2%) had at
least one adverse event after surgery; the most frequent were
biloma (12 patients, 32.4%) and pleural effusion (3 cases, 8.1%).
The majority of bilomas (10 patients) were clinically silent
(o4.0 cm in max diameter) and were observed at the 30-day
Table 1. Baseline characteristics (n¼ 39)




Comorbidities and previous pathologic conditions, n (%)
Controlled hypertension 15 (38.5)
Controlled diabetes 7 (17.9)
Episodes of hypersensitivity 5 (12.8)
Gastric ulcer 2 (5.1)
Degenerative arthropathy 2 (5.1)
COPD 2 (5.1)
Site of cancer at first diagnosis, n (%)
Colon 34 (87.2)
Rectum 5 (12.8)
Previous surgery on primary tumour, n (%)
Total 34 (87.2)
Left hemicolectomy 14 (35.9)
Anterior resection of rectum 12 (30.8)
Right hemicolectomy 8 (20.5)







Abbreviation: COPD¼ chronic obstructive pulmonary disease.
Table 2. Worst degree of toxicity
Adverse events Any grade, n (%) Grade 3, n (%)
Neutropeniaa 9 (23.1) 6 (15.4)
Hypertension 16 (41.0) 3 (7.7)
Nausea 6 (15.4) 3 (7.7)
CVC-related complications 4 (10.3) 4 (10.3)
Diarrhoea 9 (23.1) 2 (5.1)
Fatigue 3 (7.7) 1 (2.6)
Febrile neutropenia 1 (2.6) 1 (2.6)
Anaemia 2 (5.1) 0 (0)
Bleeding 2 (5.1) 0 (0)
Stomatitis 2 (5.1) 0 (0)
Abbreviation: CVC¼ central venous catheter.
aOnly grade 41 toxicity reported.
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postsurgical control CT scan; only in two cases, biloma aspiration
was necessary (Table 3).
After liver surgery, 28 (71.8%) patients started medical
treatment again, with combined bevacizumab plus FOLFIRI; 25
of them received 4 cycles as planned and 3 received 2 cycles only
because of progression (1 case) and toxicity (2 cases: fatigue and
CVC infection). Eleven patients were not candidate to resume
medical treatment after liver surgery because of surgical complica-
tions (4 cases), progressive disease or R2 at surgery (2 cases), not
operated (2 cases), finding of hepatocellular carcinoma histology,
central venous catheter complications and death because of
myocardial infarction 40 days after surgery (1 case each).
At 1 year of follow-up, the time designated for testing the
primary end -point of the study, 24 patients were alive and free
from disease progression (61.6%, 95% CI: 44.6–76.6).
On April 2012, 19 patients had died and 31 patients had an
event according to the PFS definition. Median PFS was 14 months
(95% CI: 11–24) and median OS was 38 months (95% CI: 28–NA);
PFS and OS curves are shown in Figure 1.
DISCUSSION
To the best of our knowledge, this is the first study that has
evaluated the feasibility and activity of the combination of
bevacizumab with an irinotecan-based chemotherapy as preopera-
tive treatment of initially resectable liver metastases from CRC.
Compared with the previous oxaliplatin-based studies in the
same setting (Gruenberger et al, 2008; Nordlinger et al, 2008), we
observed a higher incidence of postoperative morbidity. In our
study, 44% of the patients experienced at least one postoperative
adverse event compared with 25% of the patients in previous
oxaliplatin-based studies. The incidence of adverse events possibly
related to bevacizumab was negligible and comparable to other
studies. The difference in incidence of adverse events seems related
to a quite high rate of biliary complications (32% in our study vs
2% in previous studies). However, all such complications were
reversible and most were clinically nonsignificant. A high rate of
radiofrequency ablations associated with major liver surgery in our
study and the possible lack of reporting clinically irrelevant events
in the other studies (Gruenberger et al, 2008; Nordlinger et al,
2008) could explain this difference. Our data, however, are
consistent with a case-controlled study on the safety of
neoadjuvant bevacizumab and chemotherapy for liver metastases
from CRC, where 44% of the patients treated with bevacizumab
had postoperative complications (Tamandl et al, 2010).
In our study, one patient died 40 days after surgery for
myocardial infarction, after good postsurgical recovery and when
he was apparently well. We believe that this event is more likely
because of a combination of several cardiologic risk factors such as
diabetes mellitus, hypertension and a strong familiarity for
ischaemic heart disease rather than previous administration of
bevacizumab. However, cases of myocardial infarction have been
possibly related to bevacizumab therapy in large observational
studies (Kozloff et al, 2010; Bertolini et al, 2011).
These results confirm that the addition of bevacizumab to
standard chemotherapy as neoadjuvant treatment of resectable
liver metastases from CRC does not increase clinically relevant
postoperative morbidity and that at least a 6-week gap from the last
administration of bevacizumab and surgery is a safe interval
(Gruenberger et al, 2008; Bertolini et al, 2011).
In our study, the rates of objective response, disease control and
radical surgery (R0) were encouraging, the complete pathological
remission rate was particularly elevated, but the 1-year progres-
sion-free rate (our primary end point) was lower than the planned
one. Also, the median PFS survival of 14 months in our study is
lower than the 18.7 months reported in the EORTC study
(Nordlinger et al, 2008). However, a significant portion of patients
enrolled in our study had unfavourable prognostic factors; in
particular, 25% of patients had more than five metastatic lesions
and needed major surgery and 70% of patients had a synchronous
metastatic tumour. In the EORTC study, patients had to have four
Table 3. Surgery after neoadjuvant treatment
Type of surgery by site, n (%)
Not performed 2 (5.1)
Primary tumour 3 (7.7)
Left hemicolectomy 1 (2.6)
Right hemicolectomy 1 (2.6)




Left hepatectomy 5 (12.8)
Right hepatectomy 2 (5.1)
Enlarged right hepatectomy 2 (5.1)
Wedge resection 1 (2.6)
Other partial hepatic resections 6 (15.4)
Time from last bevacizumab, median (range), weeks 9 (6–15)
Time from last chemotherapy, median (range), weeks 6 (3–13)
Radiofrequency ablation associated, n (%) 8 (21.6)
Surgical outcome, n (%)
R0 33 (84.6)
R1 2 (5.1)
R2þ not operable 4 (10.3)
At least one surgery-related toxicity, n (%)
No 21 (56.8)
Yes 16 (43.2)
Surgery-related toxicity, n (%)
Biloma 12 (32.4)
Pleural effusion 3 (8.1)
Hepatic abscess 1 (2.7)
Fistula 1 (2.7)
Common bile duct injury 1 (2.7)
Pancreatitis 1 (2.7)














Figure 1. Kaplan–Meier estimated PFS (dashed line) and OS (solid line)
curves, with 95% confidence limits. Vertical dashes represent censored
patients.
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or less metastatic lesions and 78% had one or two deposits to the
liver. Moreover, in the EORTC study, only 34% of patients had a
synchronous metastatic tumour. In addition, consistent with the
intention-to-treat strategy, we also included three patients who were
actually found ineligible after registration and might have shortened
PFS. Despite all the limits of comparing results of different studies,
overall, our results seem similar to the previous ones obtained with
the oxaliplatin-based combinations (Gruenberger et al, 2008;
Nordlinger et al, 2008) and further suggest the potential usefulness
of bevacizumab and chemotherapy in the perioperative setting.
In conclusion, our study suggests that a neoadjuvant treatment
with an irinotecan-based chemotherapy and bevacizumab is
feasible and potentially active for patients with initially resectable
liver metastases from CRC, but further clinical trials are needed to
define whether such a treatment may be considered a reasonable
option in clinical practice.
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